Genomic/Transcriptomic Analysis for Lymphoma

Overseen By Jason Westin, MD

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: M.D. Anderson Cancer Center

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

111 Participants Needed

Trial Summary

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications.

What data supports the effectiveness of the treatment Molecular Functional Portrait for lymphoma?

Gene expression profiling has shown that different subtypes of lymphoma have unique molecular characteristics, which can influence how well they respond to treatments. This suggests that treatments like Molecular Functional Portrait, which likely use similar profiling techniques, could be effective by targeting these specific molecular features. ^{1 2 3 4 5}

How does this treatment differ from other treatments for lymphoma?

This treatment is unique because it uses genomic and transcriptomic analysis to identify specific gene expression profiles in lymphoma, allowing for more targeted and personalized therapy. Unlike traditional treatments, this approach can differentiate between subtypes of lymphoma based on their molecular characteristics, potentially leading to more effective and tailored treatment strategies. ^{1 4 5 6 7}

What is the purpose of this trial?

To learn more about the usefulness of molecular testing with the Molecular Functional (MF) Portrait (a commercial test conducted by the sponsor of this study, BostonGene) in guiding lymphoma care.

Research Team

Jason Westin

Principal Investigator

M.D. Anderson Cancer Center

Eligibility Criteria

This trial is for adults over 18 with a confirmed diagnosis of diffuse large B-cell lymphoma that needs treatment. Participants must provide written consent to be part of the study.

Inclusion Criteria

Provision of written informed consent for the study

I have been diagnosed with diffuse large B-cell lymphoma and need treatment.

Exclusion Criteria

Not applicable.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Molecular Testing

Participants undergo molecular testing using the Molecular Functional (MF) Portrait to guide lymphoma care

4-6 weeks

Follow-up

Participants are monitored for safety and effectiveness after molecular testing

4 weeks

Treatment Details

Interventions

• Molecular Functional Portrait

Trial Overview The trial is examining the effectiveness of using a commercial test called Molecular Functional Portrait by BostonGene to guide treatment decisions in patients with lymphoma.

Participant Groups

Group I: Molecular Testing Experimental Treatment 1 Intervention

Molecular Functional (MF) Portrait (a commercial test conducted by the sponsor of this study, BostonGene) in guiding lymphoma care.

Who Is Running the Clinical Trial?

M.D. Anderson Cancer Center

Lead Sponsor

Trials

3,107

Recruited

1,813,000+

Findings from Research

Gene expression profiling has identified distinct molecular subgroups within diffuse large B-cell lymphoma (DLBCL), which differ in their oncogenic mechanisms and responses to chemotherapy, highlighting the need for tailored treatment approaches.

The NF-kappaB pathway is crucial for the survival of certain DLBCL subgroups (ABC DLBCL and PMBL), suggesting it could be a potential therapeutic target, while the proliferation rate of tumors in mantle cell lymphoma significantly impacts patient survival, indicating the importance of molecular characteristics in prognosis.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

The biology of human lymphoid malignancies revealed by gene expression profiling. Staudt, LM., Dave, S.[2018]

Non-Hodgkin's lymphomas are a diverse group of diseases that can be subclassified based on the differentiation of malignant B cells and specific genetic abnormalities, highlighting the complexity of these cancers.

Gene expression profiling reveals significant molecular differences within non-Hodgkin's lymphomas, which can influence tumor behavior and patient outcomes, suggesting that understanding these signatures can improve prognostication and treatment strategies.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Gene expression signatures and outcome prediction in mature B-cell malignancies. Dave, SS.[2019]

Gene expression microarrays can effectively identify subgroups of lymphoma and leukemia, correlate with cytogenetic abnormalities, and predict patient prognosis, enhancing diagnostic accuracy.

These microarrays may lead to new therapeutic targets for chemotherapy and will likely be integrated into clinical practice to tailor treatment plans based on individual gene expression profiles.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

mRNA microarray analysis in lymphoma and leukemia. Greiner, TC.[2019]

A new method called Correlated Gene Set Analysis (CGSA) was developed to analyze transcriptional data, revealing three distinct tumor profiles in a study of 364 patients with Diffuse large B-cell lymphomas.

The study identified two main profiles with high gene expression related to proliferation and immune response, while a third profile showed low gene activation similar to normal B cells, highlighting the complexity of DLBCL and its metabolic characteristics.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Massive transcriptional perturbation in subgroups of diffuse large B-cell lymphomas. Rosolowski, M., Läuter, J., Abramov, D., et al.[2021]

Recent advances in large-scale gene expression profiling have enabled the identification of distinct gene expression signatures in lymphomas, which can differentiate between germinal center and activated B-cell phenotypes.

This differentiation reveals that large B-cell lymphomas may actually represent two distinct diseases with significantly different responses to chemotherapy, highlighting the potential for more personalized treatment approaches based on genetic profiling.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Gene expression profiling of lymphomas. Hegde, U., Wilson, WH.[2019]

This study utilized gene-expression profiling to analyze all major B-cell lymphoma types, identifying key survival genes and pathways that could serve as potential therapeutic targets.

The research highlighted common survival mechanisms across different lymphoma types, particularly focusing on the B-cell receptor (BCR) pathways, which revealed molecular differences within these lymphomas.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Functional signatures identified in B-cell non-Hodgkin lymphoma profiles. Aggarwal, M., Sánchez-Beato, M., Gómez-López, G., et al.[2019]

The study analyzed 156 cases of diffuse large B-cell lymphoma (DLBCL) and identified three distinct immunophenotypic groups using immunohistochemistry, which were then correlated with gene expression profiles obtained from microarray analysis.

Gene expression profiling revealed that DLBCL can be molecularly subgrouped, with Group B lymphomas showing unique gene expression patterns that suggest additional factors beyond cell-of-origin may influence their development, indicating a complex pathogenesis.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

[Gene expression profiling of diffuse large B-cell lymphoma in China]. Liu, YH., Li, L., Liu, G., et al.[2016]

References

1. United States pubmed.ncbi.nlm.nih.gov

The biology of human lymphoid malignancies revealed by gene expression profiling. [2018]

2. United States pubmed.ncbi.nlm.nih.gov

Gene expression signatures and outcome prediction in mature B-cell malignancies. [2019]

3. United States pubmed.ncbi.nlm.nih.gov

mRNA microarray analysis in lymphoma and leukemia. [2019]

4. United States pubmed.ncbi.nlm.nih.gov

Massive transcriptional perturbation in subgroups of diffuse large B-cell lymphomas. [2021]

5. United States pubmed.ncbi.nlm.nih.gov

Gene expression profiling of lymphomas. [2019]

6. United States pubmed.ncbi.nlm.nih.gov

Functional signatures identified in B-cell non-Hodgkin lymphoma profiles. [2019]

7. China pubmed.ncbi.nlm.nih.gov

[Gene expression profiling of diffuse large B-cell lymphoma in China]. [2016]